Reason for request
Inclusion
Clinical Benefit
Clinical Added Value
| no clinical added value |
NEVANAC 1 mg/ ml, eye drops, suspension does not offer any improvement in actual benefit (IAB V) over standard management of postoperative macular oedema associated with cataract surgery in diabetic patients. |
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
3pKQw5HUE1HW1UwY
